
This report provides a guide for selecting high-quality commercial antibodies against the transmembrane glycoprotein NMB (GPNMB) for applications in western blot, immunoprecipitation, and immunofluorescence, using a knockdown cell line as an isogenic control. This research was partially supported by the Emory-Sage-SGC TREAT-AD center, established by the National Institutes of Aging under award number U54AG065187.
Transmembrane glycoprotein NMB, Hematopoietic growth factor inducible neurokinin-1 type, antibody characterization, Q14956, antibody validation, Alzheimer's disease, GPNMB
Transmembrane glycoprotein NMB, Hematopoietic growth factor inducible neurokinin-1 type, antibody characterization, Q14956, antibody validation, Alzheimer's disease, GPNMB
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
